Victor Harbari Highlights CardioCrown’s Innovative Approach and Opens New Investment Round at OBN’s Life Sciences Event
CardioCrown proudly participated in the BioSeed Summer 2024 event, a high-energy platform organised by OBN for early-stage life sciences companies seeking Seed funding. BioSeed gathers top investors in life sciences and showcases innovative companies aiming to transform healthcare through novel technologies. CardioCrown CEO, Victor Harbari, took the stage to present the company’s disruptive stroke rehabilitation solution, NeuroVive, while officially launching our first investment round aimed at accelerating the company’s growth.
Victor Harbari, CEO of CardioCrown, commented on the event and investment opportunity: “BioSeed provides a unique opportunity to connect with investors who are passionate about life sciences and early-stage innovation. Our solution, NeuroVive, addresses a critical gap in stroke rehabilitation, and we’re excited to attract partners who share our vision of enabling better, accessible care. The launch of our investment round marks a significant step forward for CardioCrown and our mission to impact lives positively.”
Held in Reading, BioSeed offered a dynamic environment for CardioCrown to interact with potential investors, receive valuable feedback, and explore strategic collaborations. CardioCrown is eager to continue building momentum from the event and welcomes investors who are ready to support the journey of transforming stroke rehabilitation through innovative, patient-centric technology.
